Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Blood Sampling · 1 trial · 1 indication
Serogroups included MenA, MenC, MenW-135 and MenY.
Serogroups included MenA, MenC, MenW-135 and MenY.
Serogroups included MenA, MenC, MenW-135 and MenY.
Serogroups included MenA, MenC, MenW-135 and MenY.
Serogroups included MenA, MenC, MenW-135 and MenY.
| Arm | Type | Description |
|---|---|---|
| ACWY-TT group | EXPERIMENTAL | Subjects primed and boosted with the MenACWY-TT vaccine. |
| MenCCRM group | ACTIVE_COMPARATOR | Subjects primed and boosted with the Meningitec vaccine. |
| Name | Type | Description |
|---|---|---|
| Blood Sampling | PROCEDURE | At 2, 3, 4, 5, 6 years after booster vaccination. |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * A male or female who has received pri...
Blood Sampling is an investigational clinical study program by Pfizer, Inc. (PFE) involving healthy volunteers and patients with meningococcal infections. The studies evaluate immunity and antibody persistence after meningococcal vaccination. It is currently in clinical development and is not approved by the FDA.
Blood Sampling does not target a specific molecular target. It is a clinical study program that evaluates immune responses, specifically antibody persistence, after meningococcal vaccination in healthy children and adults. The studies measure the duration of immunity following vaccination.
Blood Sampling is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The program includes clinical studies sponsored by Pfizer to evaluate immunity after meningococcal vaccination.
Blood Sampling is in Phase 1 clinical development, based on the earliest-stage trial in the program. One completed trial is Phase 1, and another completed trial is Phase 3. All trials are completed, and the program is investigational, not FDA approved.
Blood Sampling includes two completed trials: NCT00518492, a Phase 1 study evaluating the duration of immunity in healthy adults who completed a prior study, and NCT01900899, a Phase 3 study of antibody persistence after meningococcal vaccine PF-06866681 in healthy children. Both trials are completed.
Blood Sampling is not the same as PF-06866681. PF-06866681 is a meningococcal vaccine evaluated in one of the Blood Sampling trials, NCT01900899. Blood Sampling refers to the overall study program, not a specific drug or vaccine.